Back in 2016, hundreds of jobs were expected for a drug manufacturing plant in the town of Dunkirk. The plant was built but ...
ImmunityBio closed the first quarter of 2026 with its strongest commercial performance to date, yet its stock price tells a different story. The disconnect highlights a massive bet by traders against ...
Financial giants have made a conspicuous bullish move on ImmunityBio. Our analysis of options history for ImmunityBio (NASDAQ:IBRX) revealed 19 unusual trades. Delving into the details, we found 57% ...
Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of ...
ImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million ...
Hosted on MSN
Why ImmunityBio stock is down more than 20% today
The United States’ Food & Drug Administration is being forced to repeatedly address the same issue with ImmunityBio’s management. Ironically, the biopharma company’s addressable actions don’t offer a ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a ...
Whales with a lot of money to spend have taken a noticeably bearish stance on ImmunityBio. Looking at options history for ImmunityBio (NASDAQ:IBRX) we detected 21 trades. If we consider the specifics ...
Hosted on MSN
Why ImmunityBio stock is soaring again today
ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter. These excellent results extend an incredible run of good news for the up-and-coming biotech stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results